These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 6809076

  • 1. A canine model of hemophilic (factor VIII:C deficiency) bleeding.
    Giles AR, Tinlin S, Greenwood R.
    Blood; 1982 Sep; 60(3):727-30. PubMed ID: 6809076
    [Abstract] [Full Text] [Related]

  • 2. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).
    Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R.
    Blood; 1984 Feb; 63(2):451-6. PubMed ID: 6419797
    [Abstract] [Full Text] [Related]

  • 3. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).
    Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N.
    Blood; 1988 Jul; 72(1):335-9. PubMed ID: 3134068
    [Abstract] [Full Text] [Related]

  • 4. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
    Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS.
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
    [Abstract] [Full Text] [Related]

  • 5. The role of factor VII in haemostasis: infusion studies of factor VIIa in a canine model of factor VIII deficiency.
    Mertens K, Briët E, Giles AR.
    Thromb Haemost; 1990 Aug 13; 64(1):138-44. PubMed ID: 2274919
    [Abstract] [Full Text] [Related]

  • 6. Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII.
    Rothschild C, Amiral J, Adam M, Meyer D.
    Haemostasis; 1990 Aug 13; 20(6):321-8. PubMed ID: 2129163
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis of von Willebrand's disease. A comparative study of diagnostic tests on nine families with von Willebrand's disease and its differential diagnosis from hemophilia and thrombocytopathy.
    Lian EC, Deykin D.
    Am J Med; 1976 Mar 13; 60(3):344-56. PubMed ID: 1083143
    [Abstract] [Full Text] [Related]

  • 8. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.
    O'Brien DP, Giles AR, Tate KM, Vehar GA.
    J Clin Invest; 1988 Jul 13; 82(1):206-11. PubMed ID: 3134399
    [Abstract] [Full Text] [Related]

  • 9. Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice.
    Eldem I, Antunes-Heck L, Subramanian R, Lasky NM, Ashworth K, Di Paola J, Girard TJ.
    J Thromb Haemost; 2024 Oct 13; 22(10):2681-2691. PubMed ID: 38925489
    [Abstract] [Full Text] [Related]

  • 10. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A.
    Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K, Sigman J, Brinkhous KM, Griggs TR, Read MS.
    Blood; 1993 May 15; 81(10):2644-51. PubMed ID: 8490173
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.
    Cooper HA, Wagner RH.
    J Clin Invest; 1974 Nov 15; 54(5):1093-9. PubMed ID: 4213756
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J.
    J Clin Invest; 1973 Nov 15; 52(11):2708-16. PubMed ID: 4542944
    [Abstract] [Full Text] [Related]

  • 15. Haemophilia A in German shepherd dogs.
    Parry BW, Howard MA, Mansell PD, Holloway SA.
    Aust Vet J; 1988 Sep 15; 65(9):276-9. PubMed ID: 3142453
    [Abstract] [Full Text] [Related]

  • 16. Use of an animal model to evaluate hemophilia therapies.
    Giles AR.
    Prog Clin Biol Res; 1984 Sep 15; 150():265-76. PubMed ID: 6431432
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of fresh-frozen plasma and cryoprecipitate in dogs with von Willebrand's disease or hemophilia A.
    Stokol T, Parry B.
    J Vet Intern Med; 1998 Sep 15; 12(2):84-92. PubMed ID: 9560764
    [Abstract] [Full Text] [Related]

  • 18. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H.
    Am J Hematol; 1985 Apr 15; 18(4):351-62. PubMed ID: 3919572
    [Abstract] [Full Text] [Related]

  • 19. The bleeding time is longer than normal in hemophilia.
    Eyster ME, Gordon RA, Ballard JO.
    Blood; 1981 Oct 15; 58(4):719-23. PubMed ID: 6791725
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S.
    Blood; 2003 Mar 01; 101(5):1734-43. PubMed ID: 12406898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.